en
Scientific article
English

Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model

Published inBlood, vol. 101, no. 2, p. 594-601
Publication date2003
Abstract

Autoimmune hemolytic anemia (AIHA) is a disease in which autoantibodies against red blood cells (RBCs) lead to their premature destruction. Most clinically significant autoantibodies are of the immunoglobulin G (IgG) type, which leads primarily to the uptake and destruction of RBCs by splenic and hepatic macrophages. Therapies such as corticosteroids and splenectomy are directed at interfering with this process. Liposomally encapsulated clodronate (dichloromethylene diphosphonate) has previously been found to be a potent antimacrophage agent. It selectively depletes animals of macrophages within 24 hours of administration by inducing apoptosis in these cells. Therefore, we hypothesized that liposomal clodronate would be a useful agent for treating AIHA. We tested this hypothesis in a mouse model of AIHA in which animals were given either anti-RBC antibodies or preopsonized RBCs. In either case, liposomal clodronate substantially decreased RBC destruction. This drug formulation was effective within hours by first blocking and then depleting phagocytic macrophages, and its action lasted for 1 to 2 weeks. Thus, in AIHA, liposomal clodronate therapy may act like a temporary, medicinal splenectomy. As such, it may prove useful in situations where rapid response to therapy is critical or other medical therapies are inadequate.

Keywords
  • Anemia, Hemolytic, Autoimmune/ drug therapy
  • Animals
  • Antibodies, Monoclonal
  • Clodronic Acid/ administration & dosage/therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Erythrocytes/immunology
  • Liposomes/therapeutic use
  • Macrophages/drug effects/immunology
  • Mice
  • Models, Animal
  • Phagocytosis/drug effects
  • Treatment Outcome
Affiliation Not a UNIGE publication
Citation (ISO format)
JORDAN, M. B. et al. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. In: Blood, 2003, vol. 101, n° 2, p. 594–601. doi: 10.1182/blood-2001-11-0061
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0006-4971
464views
1downloads

Technical informations

Creation08/27/2010 1:35:04 PM
First validation08/27/2010 1:35:04 PM
Update time03/14/2023 4:03:55 PM
Status update03/14/2023 4:03:55 PM
Last indexation02/12/2024 7:19:19 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack